Glucozid (Gliclazide) is a hypoglycemic agent of the sulfonylurea group. The hypoglycemic action of Gliclazide is related to an improvement in insulin secretion from the functioning beta cells of the pancreas.
Gliclazide is a second-generation oral hypoglycemic sulfonylurea, which stimulates the release of insulin from pancreatic beta cells by facilitating Ca++ transport across the beta-cell membrane and decreases hepatic glucose output.
Glucozid Tablet: Each Glucozid tablet contains Gliclazide BP 80 mg.
Glucozid (Gliclazide) is indicated for control of blood glucose in patients with non-insulin dependent diabetes mellitus (Type-II, maturity onset diabetes mellitus) whose hyperglycemia cannot be controlled by diet alone.
Initially, 40-80 mg daily adjusted according to response, up to 160 mg as a single dose with breakfast; higher doses divided; Max. 320 mg daily.
Hypersensitivity to sulfonylurea, diabetes complicated by ketoacidosis with coma, as a sole therapy of insulin-dependent (Type-1) diabetes mellitus, diabetes when complicated by pregnancy & breast-feeding.
Care should be exercised in patients with hepatic and/or renal impairment. In long term clinical trials patients with renal insufficiency have been treated satisfactory using Gliclazide at reduced doses.
Hypoglycemia may occur in concurrent conditions such as hepatic & renal diseases, alcohol intoxication and adrenal & pituitary insufficiency.
Gastro-intestinal disturbances such as vomiting, diarrhoea & cinstipation.
Allergic skin reactions including rash, pruritus and erythema, urticarias have been reported. These may be transient and may disappear despite continued use of the drug.
In pregnancy & Lactation: Gliclazide should not be used.
Glucozid Tablet: Each box contains 60's tablets in blister pack.
FR
DE
